| Title |
Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, August 2012
|
| DOI | 10.2147/ndt.s32581 |
| Pubmed ID | |
| Authors |
Jennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, Ibrahim Turkoz, Larry Alphs |
| Abstract |
A post hoc analysis from a multiphase trial with open-label transition and maintenance phases, a double-blind relapse prevention phase, and an optional open-label extension examined the long-term tolerability with continuous once-monthly injectable paliperidone palmitate 39, 78, 117, or 156 mg (25, 50, 75, or 100 mg equivalents [mg eq] of paliperidone) in subjects with recently diagnosed (≤5 years; n = 216) versus chronic illness (>5 years; n = 429) schizophrenia. |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 63 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 23% |
| Student > Bachelor | 9 | 14% |
| Student > Master | 7 | 11% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 5 | 8% |
| Other | 12 | 18% |
| Unknown | 12 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 34% |
| Psychology | 8 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Other | 10 | 15% |
| Unknown | 16 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2012.
All research outputs
#22,759,452
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,584
of 3,132 outputs
Outputs of similar age
#161,506
of 179,163 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#15
of 15 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,163 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.